Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic ... the FDA declared that Eli Lilly's weight loss and diabetes ...

Novo and Lilly have invested billions to ramp up supply of their treatments, which lagged demand for most of last year. All doses of Ozempic and Wegovy were listed as available on the FDA ...

In August, drug manufacturer Eli Lilly began sending cease-and-desist ... compounded drug that is essentially a copy of Ozempic or Wegovy is illegal.” The company has already filed more than ...

Compounding pharmacies that have been selling hundreds of thousands of doses of copies of Lilly's Zepbound and Novo's Wegovy while the medicines were in shortage are running out of time to produce ...

This is similar to what the FDA has granted compounding pharmacies making copies of Eli Lilly's diabetes and weight ... Ozempic, and Wegovy (GLP-1 drugs) has skyrocketed, but supply shortages ...

Eli Lilly is growing faster with Zepbound and Mounjaro ... Novo Nordisk also cut profits in the second quarter due to weaker Wegovy sales and rebates and it missed revenue estimates in the ...